Pirfenidone : Anti-fibrotic agent with a potential therapeutic role in the management of transplantation patientsDOSANJH, Amrita.European journal of pharmacology. 2006, Vol 536, Num 3, pp 219-222, issn 0014-2999, 4 p.Article

Pharmacokinetics, Safety and Tolerability of Pirfenidone and its Major Metabolite after Single and Multiple Oral Doses in Healthy Chinese Subjects under Fed ConditionsHUANG, N.-Y; DING, L; WANG, J et al.Drug research (Stuttgart. 2013. Print). 2013, Vol 63, Num 8, pp 388-395, issn 2194-9379, 8 p.Article

Pirfenidone in idiopathic pulmonary fibrosisTANIGUCHI, H; EBINA, M; TAKEUCHI, M et al.The European respiratory journal. 2010, Vol 35, Num 4, pp 821-829, issn 0903-1936, 9 p.Article

Potent antioxidant role of Pirfenidone in experimental cirrhosisSALAZAR-MONTES, Adriana; RUIZ-CORRO, Luis; LOPEZ-REYES, Alberto et al.European journal of pharmacology. 2008, Vol 595, Num 1-3, pp 69-77, issn 0014-2999, 9 p.Article

Pirfenidone for the treatment of idiopathic pulmonary fibrosisXAUBET, Antoni; SERRANO-MOLLAR, Anna; ANCOCHEA, Julio et al.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 2, pp 275-281, issn 1465-6566, 7 p.Article

Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosisKAKUGAWA, T; MUKAE, H; HAYASHI, T et al.The European respiratory journal. 2004, Vol 24, Num 1, pp 57-65, issn 0903-1936, 9 p.Article

Traitement de la fibrose pulmonaire idiopathique par pirfénidone: premiers retours d'expérience = Treatment of idiopathic pulmonary fibrosis with pirfenidone: preliminary lessonsWEMEAU-STERVINOU, L; TRACLET, J; BORIE, R et al.Revue des maladies respiratoires actualités (Print). 2012, Vol 4, issn 1877-1203, S26-S28, SUP1Article

Pirfenidone : A novel potential therapeutic agent in the management of chronic allograft rejectionDOSANJH, A.Transplantation proceedings. 2007, Vol 39, Num 7, pp 2153-2156, issn 0041-1345, 4 p.Conference Paper

Pirfenidone: A Potential New Therapy for Restrictive Allograft Syndrome?VOS, R; VERLEDEN, S. E; VERLEDEN, G. M et al.American journal of transplantation (Print). 2013, Vol 13, Num 11, pp 3035-3040, issn 1600-6135, 6 p.Article

Renoprotective properties of pirfenidone in subtotally nephrectomized ratsTAKAKUTA, Koji; FUJIMORI, Akira; CHIKANISHI, Toshihiro et al.European journal of pharmacology. 2010, Vol 629, Num 1-3, pp 118-124, issn 0014-2999, 7 p.Article

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosisAZUMA, Arata; NUKIWA, Toshihiro; SATO, Atsuhiko et al.American journal of respiratory and critical care medicine. 2005, Vol 171, Num 9, pp 1040-1047, issn 1073-449X, 8 p.Article

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisKING, Talmadge E; BRADFORD, Williamson Z; LEDERER, David J et al.The New England journal of medicine. 2014, Vol 370, Num 22, pp 2083-2092, issn 0028-4793, 10 p.Article

Pirfenidone: A Novel Agent for the Treatment of Idiopathic Pulmonary FibrosisPOTTS, Jason; YOGARATNAM, Dinesh.The Annals of pharmacotherapy. 2013, Vol 47, Num 3, pp 361-367, issn 1060-0280, 7 p.Article

Effects of Pirfenidone on Proliferation, Migration, and Collagen Contraction of Human Tenon's Fibroblasts In VitroXIANCHAI LIN; MINBIN YU; KAILI WU et al.Investigative ophthalmology & visual science. 2009, Vol 50, Num 8, pp 3763-3770, issn 0146-0404, 8 p.Article

Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patientsTANIYAMA, M; OHBAYASHI, S; NARITA, M et al.European journal of clinical pharmacology. 1997, Vol 52, Num 1, pp 77-78, issn 0031-6970Article

Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicitySHIHAB, Fuad S; BENNETT, William M; HONG YI et al.Transplantation. 2005, Vol 79, Num 4, pp 419-426, issn 0041-1337, 8 p.Article

Alveolar Macrophage Dysregulation in Hermansky-Pudlak Syndrome Type 1ROUHANI, Farshid N; BRANTLY, Mark L; MARKELLO, Thomas C et al.American journal of respiratory and critical care medicine. 2009, Vol 180, Num 11, pp 1114-1121, issn 1073-449X, 8 p.Article

Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary FibrosisCOVVEY, Jordan R; MANCL, Erin E.The Annals of pharmacotherapy. 2014, Vol 48, Num 12, pp 1611-1619, issn 1060-0280, 9 p.Article

The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicityBROOK, Nicholas R; WALLER, Julian R; BICKNELL, Gareth R et al.The Journal of surgical research. 2005, Vol 125, Num 2, pp 137-143, issn 0022-4804, 7 p.Article

Pirfenidone inhibits macrophage infiltration in 5/6 nephrectomized ratsCHEN, Jun-Feng; NI, Hai-Feng; PAN, Ming-Ming et al.American journal of physiology. Renal physiology. 2013, Vol 73, Num 3, issn 1931-857X, F676-F685Article

Effects of three anti-TNF-α drugs : Etanercept, infliximab and pirfenidone on release of TNF-α in medium and TNF-α associated with the cell in vitroGRATTENDICK, K. J; NAKASHIMA, J. M; FENG, L et al.International immunopharmacology. 2008, Vol 8, Num 5, pp 679-687, issn 1567-5769, 9 p.Article

Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicityCARD, Jeffrey W; RACZ, William J; BRIEN, James F et al.Toxicological sciences (Print). 2003, Vol 75, Num 1, pp 169-180, issn 1096-6080, 12 p.Article

Inhalable Powder Formulation of Pirfenidone with Reduced Phototoxic Risk for Treatment of Pulmonary FibrosisONOUE, Satomi; SETO, Yoshiki; KATO, Masashi et al.Pharmaceutical research. 2013, Vol 30, Num 6, pp 1586-1596, issn 0724-8741, 11 p.Article

Synthesis and structure-activity relationship of 5-substituent-2(1H)-pyridone derivatives as anti-fibrosis agentsJUN CHEN; LU, Miao-Miao; BIN LIU et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 6, pp 2300-2302, issn 0960-894X, 3 p.Article

Pirfenidone for Diabetic NephropathySHARMA, Kumar; IX, Joachim H; DONOHUE, Michael et al.Journal of the American Society of Nephrology. 2011, Vol 22, Num 6, pp 1144-1151, issn 1046-6673, 8 p.Article